Elizabeth Holmes, the founder of Theranos, is serving an 11-year prison sentence for defrauding investors through her controversial blood-testing startup. Meanwhile, her partner is in the process of raising $50 million for a new venture focused on blood testing.
In a surprising turn, the startup, named Haemanthus—after the blood lily—is positioning itself as “the future of diagnostics” with what it calls “a radically new approach to health testing.” This echoes the early claims made by Theranos.
Questions arise about why her partner, described as an heir to a hotel fortune, is pursuing a path in blood testing. Perhaps it’s a continuation of the family legacy?
According to reports, the company has already “raised millions,” primarily from friends, family, and supporters. Initial plans include testing pets for diseases before eventually expanding to human testing.
The online community has expressed disbelief over this development, with many finding humor in the situation. One user humorously clarified that the astonishing story is indeed real and not a prank or speculation.
In a landscape filled with bizarre headlines, it’s astonishing how often new news continues to astonish.
